Bills Committee on Chinese Medicine (Amendment) Bill 2017

List of follow-up actions required of the Administration arising from the discussion at the meeting on 22 January 2018

The Administration was requested to:

(a) in respect of the licensing requirements under the Chinese Medicines Regulation (Cap. 549F) that licensed Chinese medicines traders had the duty to set up and maintain a system of control to enable the rapid and, so far as practicable, complete recall of the Chinese medicine products sold or distributed by the licence holder concerned, provide information on the composition and functions of the Chinese Medicines Board ("CMB") which was the licensing authority, in particular its work in relation to the system of control referred above;

(b) provide information on the mechanism put in place by the Department of Health, including inspections conducted, to ensure that the licensed wholesalers of Chinese herbal medicines had purchased herbal medicines or processed herbal medicines only from reputable suppliers as required in the Practising Guidelines for Wholesalers of Chinese Herbal Medicines, and the disciplinary actions taken by CMB and/or prosecution actions taken against the non-complying wholesalers; and

(c) in respect of herbal teas containing Chinese medicines ingredients which were sold in Chinese herbal tea shops that were subject to the regulation of the Public Health and Municipal Services Ordinance (Cap. 132), provide information on:

    (i) the number of inspection and sample testing, if any, carried out by the Food and Environmental Hygiene Department in 2017 to ensure that these herbal teas were fit for human consumption; and

    (ii) the number of cases whereby the herbal teas concerned were found unfit for human consumption and the prosecution actions taken.

Council Business Division 2
Legislative Council Secretariat
15 February 2018